Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company focused on obesity and metabolic health disorders, has announced its participation in two upcoming investor conferences in February 2025.
The company will participate in the BIO CEO & Investor Conference in New York on February 10, where they will join a panel discussion on 'Obesity: Next Medicines with Impact' at 11:00 AM ET. Additionally, Skye will present a corporate overview at the virtual Oppenheimer 35th Healthcare Life Sciences Conference on February 12 at 12:00 PM ET. A webcast of the presentation will be available on Skye's website
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.